Trial Now Recruiting: Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) (NCT07447648)
WHY IT MATTERS
If you have HoFH, this trial offers access to Evinacumab—a newer cholesterol-lowering therapy—and detailed imaging to measure whether it's actually reducing the dangerous plaque buildup in your coronary arteries.
Researchers are looking for 52 patients with a rare genetic condition called homozygous familial hypercholesterolemia (HoFH) to join a study. HoFH causes dangerously high cholesterol levels from birth, which leads to heart disease at a young age. This study will test whether a new cholesterol-lowering drug called Evinacumab, combined with other treatments, can reduce the buildup of plaque in heart arteries.
NCT ID: NCT07447648 Status: RECRUITING Conditions: Homozygous Familial Hypercholesterolemia (HoFH), Coronary Computed Tomography Angiography Enrollment: 52 Sponsor: Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) Summary: This observational, multicenter, retrospective and prospective study aims to evaluate the impact of intensified lipid-lowering therapy including Evinacumab on coronary atherosclerotic plaque burden in patients with Homozygous Familial Hypercholesterolemia (HoFH). HoFH is a rare genetic disorder characterized by extremely elevated low-density lipoprotein cholesterol (LDL-C) levels from early life and a markedly increased risk of premature atherosclerotic cardiovascular disease. Despite combinati
YOU CAN ACT ON THIS
If you have been diagnosed with homozygous familial hypercholesterolemia, contact your cardiologist or lipid specialist now to ask if you meet the eligibility criteria for this 52-patient trial (NCT07447648), which is actively recruiting.